🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"This is the first time we have real-world confirmation of this magnitude and we never expected that number," says Albert Bourla. The Pfizer CEO reacts to data from Israel showing his company's vaccine blocks 94% of asymptomatic infections. cnb.cx/3cjwNLH

New data from Israel - poor humoral responses to 2x doses of Pfizer vaccine in people treated with Fingolimod and Ocrelizumab #MSMastersForum

#WorldMSDay 🌍🧠 Moving towards precision medicine in MS with sNfL w/ Mark S Freedman of The Ottawa Hospital: ow.ly/pzVm50E6l7i #MSConnections World MS Day #MultScler #MultipleSclerosis

1st look at the Consensus statement on Neurofilament Biomarkers in Multiple Sclerosis cmscscholar.org/ijmsc-cmsc-con… CMSC Mark S Freedman the_MSBlog

Anti-CD20 drugs (Ocrevus, Kesimpta, rituximab) decrease the probability of anti-SARS-COV-2 antibodies after vaccination by 97%! Gilenya decreases the probability by 59%. I suspect this doesn't correlate well with "real-world" immunity though.

The most important and largest randomized controlked study yet using MSC to treat MS

Now if he could just take us where no current former captain has done before...

Ponesimod in RRMS – long-term clinical trials ift.tt/jMyBwxk

When Drs. Atkins and Freedman first proposed using #StemCells to halt #MultipleSclerosis, many were skeptical. 24 years later, this groundbreaking treatment is eliminating the disease for patients like Geneviève. Learn how it works: fal.cn/3sjmr

New scientist alert! Dr. Gauruv Bose Bose aims to use AI and #BigData to predict the course of #MultipleSclerosis. ohri.ca/newsroom/story…

Meet the international speakers of SMSC 2023! Join us and learn from the experts in the field of #Multiple_Sclerosis 📌 Register now:(smscsa.co) 🗓 May 26-27, 2023 📍 Dhahran Expo, Eastern Province #SMSC_2023 #WorldMSDay

At the recent ACTRIMS/ECTRIMS meeting in Milan, ACTRIMS was asked not to make a statement regarding the Hamas-Israeli conflict to avoid detracting from a great scientific meeting. We no longer need to remain silent https://www.actrims/news

Mark S Freedman Mark, thank you the statement and for supporting Israeli and Palestinian trainees for Palm Beach ACTRIMS meeting 👏👏👏

I am relieved that Liz Magill resigned as President of Penn. This week, I viewed a highly restricted Israel Defense Forces video of the Oct 7 Hamas massacre. I was sickened by video images I can never "unsee" and appalled by university presidents, like Liz Magill, who are OK with calls for

Editor pick from March issue Mark S Freedman S Gnanapavan & coll Discuss studies supporting neurofilament light chain (NfL) as a biomarker in multiple sclerosis and present practical guidance for obtaining NfL samples and interpreting findings Read bit.ly/3vkWjOg

Editor pick from March issue Mark S Freedman S Gnanapavan & coll Discuss studies supporting neurofilament light chain (NfL) as a biomarker in multiple sclerosis and present practical guidance for obtaining NfL samples and interpreting findings Read bit.ly/3vkWjOg

Great to be on a panel discussion on detecting subtle progression in people living with #MS. Healthcare providers must improve our ability to listen to our patients to pickup progression. New trial outcome measures needed to detect subtle progression. #ECTRIMS2024 Mark S Freedman

We mourn the loss of Prof. Giancarlo Comi, a pioneering neurologist in multiple sclerosis research. As a former ECTRIMS council member and European Charcot Foundation (European Charcot Foundation) founder, his contributions have profoundly shaped the field and patient care globally.

Systematic review on serum neurofilament light chain (sNfL) link.springer.com/article/10.100…

I was deeply honored to be chosen as a "Giant" in Research by the CMSC